Abstracts

THE DUAL FUNCTION OF THE ADENOSINE PATHWAY IN THE LIPOSARCOMA TUMOR MICROENVIRONMENT

Jacqueline Oliva1, Yonghee Lee2, Rebeca Rodriguez3, Katarzyna Tomczak4, Davis Ingram5, Xiao Zhou5, Vinod Rav!, Anthony Conley6, John Livingston1, Joseph Ludwig7, Neeta Somaiah8, Cara Haymaker9, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Wellsley College, Houston, TX, USA

Background Single agent anti-PD1 therapy has shown limited clinical benefit in liposarcoma, but combination with anti-CTLA-4 demonstrated a higher response rate. In the MDACC study NCT02815995, combining anti-CTLA4 and anti-PDL1 across multiple soft-tissue sarcomas increased CD73, PD-1, and OX40 expression in T cells early on treatment. The adenosine pathway, which includes CD73 and the A2A receptor, induces immunosuppression and protects from antitumoral responses. This pathway is related to immune therapy resistance, metastasis, and poor prognosis. Conversely, CD73+ T cells have long-lived memory and higher proliferation and survival, suggesting a dual role of the pathway. We hypothesized that adenosine would negatively correlate with TIL expansion and function.

Methods Surgically resected liposarcoma samples (n=41) were divided for fresh tissue phenotyping by flow cytometry, TIL expansion, and quantification of tissue adenosine, cytokines, and adipokines. The phenotypic analysis included: CD73, A2AR, PD-1, Tim3, CTLA-4, LAG3, OX40, ICOS and 41BB markers. TIL 3.0 expansion protocol was performed, and expanded TIL were assessed for cytotoxicity by IFN-γ production and metabolic activity (ROS, mitochondrial activity) by flow cytometry.

Results We found high heterogeneity in the frequency of CD45+ cells (0-88.3%), CD4+ and CD8+ T-cell infiltration, and expression of PD-1 (0.66-59.60%) and 99-76.6% respectively, CD73 (CD4+ 0-40.97%, CD8+ 0-34.04%), and A2AR (mean CD4+ 0-6.6%, CD8+ 0-17.96%), with no co-expression of CD73 and A2AR. Interestingly adenosine concentration was highly variable (0-84.05 nmol/g tissue) but did not correlate with TIL phenotype or tissue cytokines. Tumors were rich in growth factors and chemokines but lacked a pro-inflammatory profile. The success of TIL expansion was 50% (n=24 cases) in samples with a count of 300 CD3+ events in the fresh tissue by flow analysis. The frequency of CD8+CD73+ TIL was significantly higher in cases with successful TIL expansion (p=0.041). The expanded TIL phenotype showed CD73 expression (range: CD4+ 0.67-29% and CD8+ 0.85-13.9%), upregulation of A2AR (range: 0.2-15.40% and 1.44-87.6%), IFN-γ production was related to intrinsic metabolic profiles by mitochondrial mass and ROS production (n=8).

Conclusions A heterogeneous adenosine landscape was found in liposarcoma, A2AR but not CD73 correlated with mitochondrial dysfunction and reduced cytotoxicity. Conversely CD73+ TIL were more likely to expand. Our results indicate a dichotomy in two key members in the adenosine pathway in liposarcoma and suggest that CD73 might play a positive role in TIL function.

Acknowledgements Patients and their families.

CCSG Metabolomics Core (Grant P30CA016672) and Philanthropy support provided by a generous donation by the William Oates family

REFERENCES

Ethics Approval This study was written and conducted in accordance with the principles from the Declaration of Helsinki. Written informed consent was provided by all study participants or their legal representatives. The study was approved by the University of Texas MD Anderson Cancer Center’s Institutional Review Board.


A1082 J Immunother Cancer 2022;10(Suppl 2):A1–A1595